Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction.

Shimada, Midori; Fukuda, Minoru; Fukuda, Masaaki; Kitazaki, Takeshi; Hashiguchi, Kohji; Ikeda, Takaya; Yamaguchi, Hiroyuki; Nakatomi, Katsumi; Ashizawa, Kazuto; Mukae, Hiroshi

Shimada, Midori; Fukuda, Minoru; Fukuda, Masaaki; Kitazaki, Takeshi; Hashiguchi, Kohji; Ikeda, Takaya; Yamaguchi, Hiroyuki; Nakatomi, Katsumi; Ashizawa, Kazuto; Mukae, Hiroshi.

Afiliación

Shimada M; Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences.
Fukuda M; Department of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Hospital.
Fukuda M; Department of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Hospital.
Kitazaki T; Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan.
Hashiguchi K; Department of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Hospital.
Ikeda T; Department of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Hospital.
Yamaguchi H; Department of Respiratory Medicine, Japanese Red Cross Nagasaki Genbaku Hospital.
Nakatomi K; Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences.
Ashizawa K; Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences.
Mukae H; Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences.

Onco Targets Ther ; 10: 3211-3214, 2017.

Article en En | MEDLINE | ID: mdl-28721071

Palabras clave

ALK; alectinib; lung cancer; renal dysfunction

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Onco Targets Ther Año: 2017 Tipo del documento: Article